Circassia (United Kingdom) a clinical-stage specialty biopharmaceutical focused on therapeutic T-cell vaccines for allergies and organ transplant rejection, closed a $25M Series C financing. Participants include Imperial Innovations, Invesco Perpetual and Lansdowne Partners.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Bellicum Pharmaceuticals (Houston, TX) a clinical-stage biopharmaceutical company focused on immune-modulating therapeutic vaccines for prostate cancer, closed a $4.5M Series A financing. Particiapnts include the Texas Emerging Technology Fund.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Juvaris BioTherapeutics (Pleasanton, CA) a clinical-stage biopharma company focused on adjuvanted vaccines for seasonal flu and immunotherapeutics for Leukemia and animal health, closed a $12.5M Series B financing. Participants include SV Life Sciences and Kleiner Perkins Caufield & Byers.

*Estimated first close of round

NanoBio (Ann Arbor, MA) a clinical-stage company focused on topical antiinfectives and mucosal vaccines for the treatment and prevention of herpes labialis, onychomycosis, acne and cystic fibrosis closed a $10M Series B financing, bringing the total round to $22M. Participants include Perseus.

Profectus BioSciences (Baltimore, MD) a clinical-stage biopharmaceutical focused on the development of vaccines for chronic viral infections, closed a $5M Series C financing. Participants include Cross Atlantic Capital Partners.

VaxInnate (Cranbury, NJ) a clinical-stage vaccine company focused on infectious disease including flu, malaria, dengue, papillomavirus, and respiratory syncytial virus, closed a $30M Series D financing. Participants include Wellcome Trust, New Leaf Venture Partners, Canaan Partners, HealthCare Ventures, Oxford Bioscience Partners, MedImmune Ventures and CHL Medical Partners.

Parasol Therapeutics (Cambridge, MA) a seed-stage company focused on treatments and diagnostics for influenza, closed a $3.3M Series A financing. Participants include Polaris Venture Partners, Flagship Ventures and Lux Capital.

BioVex (Woburn, MA) a clinical-stage therapeutic vaccine company focused on metastatic melanoma, closed a $40M Series F financing. Participants include Forbion Capital Partners, Credit Agricole Private Equity, Harris & Harris Group, Innoven Partners, New Science Ventures, Triathlon Medical Venture Partners and Scottish Equity Partners.

GlycoVaxyn (Switzerland) a preclinical-stage company developing vaccines focused on bacterial caused disease, closed a $22M Series B financing. Participants include Edmond de Rothschild Investment Partners, Index Ventures and Sofinnova Partners.

NanoBio (Ann Arbor, MI) a clinical-stage company focused on topical antiinfectives and mucosal vaccines for the treatment and prevention of herpes labialis, onychomycosis, acne and cystic fibrosis closed a $12M Series B financing. Participants include Perseus.